| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Contineum Therapeutics (NASDAQ:CTNM) through any online brokerage.
Other companies in Contineum Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Contineum Therapeutics has a consensus price target of $22.17.
The stock price for Contineum Therapeutics (NASDAQ: CTNM) is $7.33 last updated October 19, 2026 at 4:53 PM EDT.
There are no upcoming dividends for Contineum Therapeutics.
Contineum Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Contineum Therapeutics.
Contineum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
